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1. Introduction 
Retinoblastoma accounts for 6% of pediatric malignancies under the age of 5 years in the 
United States, (Broaddus et al., 2008) and epidemiological data suggest that the incidence is 
standard across populations (Kivelä, 2009). Despite its rarity, observations about the 
pathogenesis of this disease have enhanced our understanding of genetic cancer syndromes. 
Germinal or hereditary cases comprise approximately 40% of retinoblastoma cases, and all 
patients with the germinal RB1 mutation are at risk for secondary malignancies. According 
to recent reports, some retinoblastoma patients exhibit varying degrees of mosaicism for the 
RB1 mutation, allowing them to develop second primary malignancies in addition to those 
with standard hereditary retinoblastoma. These cancers occur in various anatomic locations 
such as the skull and long bones, soft tissues, skin, nasal cavity, brain, lung, and breast. The 
pattern of development and risk for these tumors are heavily influenced by the methods of 
treatment for retinoblastoma, which have shifted from enucleation to external-beam 
radiation to systemic chemotherapy with focal treatments. Investigations of the benefits of 
intra-arterial chemotherapy are ongoing with the hopes of reducing the morbidities 
associated with systemic therapy. Due to these improving treatment techniques, 10-year 
survival rates of primary retinoblastoma have been among the highest of all childhood 
cancers at greater than 92% in the United States and other developed countries since 1975 
(Kaatsch, 2010; Linabery & Ross, 2008). Secondary malignancies have thus become an 
increasingly significant topic of interest as they are the leading cause of death of germinal 
retinoblastoma survivors in the United States. 
2. History 
The number of retinoblastoma survivors and their offspring increased during the mid-
twentieth century as methods of detection and treatment regimens improved. This increased 
survival greatly enhanced insight into the pathology of retinoblastoma, including the 
identification of the somatic and germ-line mutation variants of sporadic retinoblastoma 
(Albert, 1987). Examination of the differences between unilateral and bilateral disease 
prompted the two-hit model of retinoblastoma by Knudson in 1971 (Knudson, 1971). This 
proposal led to the realization that hereditary patients carry a germinally inactivated RB1 
allele in all cells of the body before somatically suffering inactivation of the normal allele in 
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a retinal cell or cells. Without the tumor suppressive activity of a functional pRB, these 
patients become susceptible to developing second nonocular cancers. Before the 1970s, the 
majority of new malignancies in survivors of retinoblastoma arose in the prior radiation 
fields, and could be labeled as radiation-induced neoplasias (Zimmerman, 1985). Secondary 
tumors arising from non-irradiated areas were initially reported by Jensen and Miller 
(Jensen & Miller, 1971) in 1971. In 1976 Abramson et al (Abramson, 1976) demonstrated the 
association of the risk of nonocular cancers with heritable retinoblastoma. Jakobiec et al. 
(Jakobiec et al., 1977) and Bader et al. (Bader et al., 1980) are responsible for the initial 
identification of trilateral retinoblastoma, the occurrence of a tumor in the pineal gland or 
parasellar region in addition to having hereditary retinoblastoma. Subsequently, the types of 
second cancers, risk factors for development of second cancers, and survival after 
development of second cancers have been extensively reviewed. 
3. Epidemiology 
Survivors of retinoblastoma who carry the RB1 mutation are not at an increased risk of dying 
from any cause when compared to those who have not had retinoblastoma, with the exception 
of second non-ocular cancers. The incidence of secondary malignancies in germinal 
retinoblastoma survivors has been the topic of study in many reports, (Abramson et al., 2001; 
Eng et al., 1993; Fletcher et al., 2004; Kleinerman et al., 2005; MacCarthy et al., 2009; Marees et 
al., 2008; Moll et al., 1997; Wong et al., 1997; & Yu et al., 2009) but the variance of sample size 
and study design in these reports has made interpretation of the cumulative incidence 
difficult. Using reported cumulative risk rates from sizeable studies with appreciable long-
term follow-up, incidence rates are approximately 0.5% to 1% per year. These are gross 
estimates used for comparison across studies (Fletcher et al., 2004). Long-term follow-up of a 
large cohort of 1,601 retinoblastoma survivors in the United States revealed a cumulative risk 
of a second cancer among hereditary patients of 36% at 50 years compared to only 5.7% in 
patients with sporadic retinoblastoma (Kleinerman et al., 2005). Similar results were observed 
in a large cohort of 1927 retinoblastoma survivors in Britain with a cumulative overall 
incidence of second cancer among hereditary patients of 43% at 50 years compared to only 
4.9% in nonhereditary retinoblastoma survivors (MacCarthy et al., 2009). 
Epidemiologic evidence has indicated that incidence rates may vary based on the treatment 
received by the patient and the age at which it is received. It has been well documented that 
patients who were irradiated for retinoblastoma have a higher incidence of secondary 
malignancies than those who were not irradiated. Furthermore, 50% of patients who 
developed retinoblastoma within the first month of life and were treated with radiotherapy 
developed second cancers by 24 years of age (Abramson et al., 2002a). The incidence of 
retinoblastoma has remained stable over the last 30 years in the United States, (Broaddus et 
al., 2008) but the cumulative incidence of new cancers has declined as the dosage and use of 
radiotherapy continues to decrease (Kleinerman et al., 2005). As new and better therapies 
are developed this trend is likely to continue. 
4. Types of second tumors 
4.1 Benign 
In a survey of 898 retinoblastoma survivors, Li et al. (Li et al., 1997) reported a surprising 
number of lipomas in patients with this hereditary disease. Rieder et al. (Rieder et al., 1998) 
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futher promoted the idea that a predisposing RB1 gene mutation may play a role in the 
development of lipomas in retinoblastoma patients, by demonstrating the recurrent loss of 
the same RB1 allele in two different lipomas in the same patient. Others have reported a 
genetic linkage between a specific RB1 mutation and the development of multiple lipomas, 
postulating that there is a linked polymorphic allele which acts as a modifying factor by 
affecting expression of the RB1 gene mutation (Genuardi et al., 2001). These lipomas, when 
found in hereditary retinoblastoma patients, are preferentially located on the face, neck, 
shoulders, and upper chest (Genuardi et al., 2001). Li et al. (Li et al., 1997) additionally, 
found twice as many patients with hereditary retinoblastoma and lipomas developed 
secondary malignancies when compared to those without lipomas. These results suggest 
that the presence of lipomas may indicate an elevated second cancer risk and that certain 
germline mutations in the RB1 gene may predispose the patient to both lipomas and 
secondary tumors. This finding may have future implications on follow up and screening of 
retinoblastoma survivors for second malignancies. 
4.2 Malignant 
The most common second malignancies appear to be closely related to the initial method of 
treatment for retinoblastoma. In the United States and the Netherlands, where external 
beam radiation was commonly used as primary therapy, osteosarcomas of the skull and 
long bones, soft tissue sarcomas, cutaneous melanomas, brain tumors including trilateral 
retinoblastoma, tumors of the nasal cavity, Hodgkin’s disease, lung cancer, and breast 
cancer predominate (Kleinerman et al., 2005; MacCarthy et al., 2009; Marees et al., 2008; 
Wong et al., 1997). In Britain, where the majority of retinoblastoma survivors did not 
undergo external beam radiation, epithelial cancers were more common, especially as 
follow-up extended into the seventh decade (Fletcher et al., 2004). As trends in treatment 
continue to change and the length of follow-up continues to increase, the rate of bone and 
soft tissue cancer development may decline while the rate of epithelial cancers are likely to 
increase. 
Studies on the development of additional tumors (third, fourth and fifth) in survivors of 
retinoblastoma and second malignancies have been performed, although without 
consistent results (Abramson et al., 2001, Marees et al., 2010). Epidemiologically, 
Abramson et al. (Abramson et al., 2001) demonstrated an incidence rate of approximately 
2% per year from the time of diagnosis of the second malignancy. Marees et al. (Marees et 
al., 2010) reported an 8-fold increase in the risk for a third primary neoplasm compared to 
the general population. The latency period decreases as each additional cancer is 
diagnosed. Historically, male retinoblastoma survivors were reported to have a higher 
incidence of third malignancies, primarily because females had an increased overall 
mortality rate from second malignancies (Abramson et al., 2001; Eng et al., 1993). More 
recent studies, however, have no longer identified an increase in female mortality from 
second malignancies (Marees et al., 2009; Yu et al., 2009). Abramson et al. (Abramson et 
al., 2001) reported a predictable pattern for third, fourth, and fifth malignancy 
development based on location of the second tumor. In that study, patients with second 
malignancies of the skin or skull were more likely to develop an additional tumor in the 
skin and skull, respectively. Marees et al. (Marees et al., 2010) did not find this predictable 
pattern in a Dutch cohort.  
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4.3 Trilateral retinoblastoma 
Trilateral retinoblastoma is a well-recognized syndrome that consists of unilateral or 
bilateral retinoblastoma associated with an intracranial primitive neuroectodermal tumor. 
The intracranial mass is often located in the pineal region, but may also be a suprasellar or 
parasellar tumor. A specific subset of patients are more likely to develop these lesions 
including those with a family history of retinoblastoma, bilateral disease, diagnosis within 
the first 6 months of life, and prior treatment with external beam radiation. Reviews of 
published cases of trilateral retinoblastoma from 1966 through 1998 and 1977 through 1997 
demonstrated a poor prognosis with a median survival of 6 to 9 months (Kivelä, 1999, 
Paulino, 1999). More recently, a small series from Brazil corroborated the dismal prognosis 
by reporting a median survival of 10 months (Antoneli et al., 2007). As such, these tumors 
are the most frequent cause of death in retinoblastoma survivors between the ages of 5 to 10 
years (Blach et al., 1994). However, promising new studies indicate that treatment of 
trilateral retinoblastoma with intensive chemotherapy may offer an improved prognosis 
(Dimaras et al., 2011; Dunkel et al., 2009). 
The incidence of trilateral retinoblastoma has decreased recently, but the underlying cause 
for this shift remains controversial. Shields et al. (Shields et al., 2001) suggested that 
chemoreduction therapy may reduce the incidence of pineoblastoma. Of the 99 at risk 
patients treated with chemoreduction in that study, none developed pineoblastoma. 
However, 1 of 18 (5.5%) at risk patients not treated with chemoreduction developed 
trilateral retinoblastoma, which is consistent with the rate of development in other 
published series. None of the patients in the chemoreduction group were treated with 
radiotherapy, prompting some to suggest that the declining incidence of pineoblastomas 
may be due to the declining use of external-beam radiation therapy (Moll et al., 2002). An 
analysis of the published literature by Woo et al. in 2010 reported an approximately equal 
number of pinealomas in irradiated patients and those who were not irradiated, suggesting 
that radiation therapy may not play as significant a role in trilateral retinoblastoma as 
previously suspected (Woo & Harbour, 2010). Additional studies are needed to elucidate the 
relationship between chemoreduction and trilateral retinoblastoma.  
It is important to note that the classification of these tumors as a second malignancy as 
opposed to a variant of the primary tumor is controversial. They often cannot be 
differentiated from retinoblastoma histologically and have occasionally been documented to 
occur prior to the development of ocular manifestations in some patients (Jurkiewicz et al., 
2009; Moll et al., 2001) For these reasons, some studies have not included trilateral 
retinoblastoma as a second malignancy, but the classification has varied over the years 
causing some discrepancy in the literature.  
4.4 Independent second non-ocular retinoblastoma 
Soh et al. (Soh et al., 2011) reported a case of an independent retinoblastoma located in the 
ovary of a bilateral ophthalmic retinoblastoma survivor. Eighteen years after radiation of the 
right eye and enucleation of the left eye, the patient was found to have a large left ovarian 
tumor involving the fallopian tube, mesentery, and lymph nodes. Histologically, the 
concurrent presence of Homer Wright and Flexner-Wintersteiner rosettes confirmed the 
identification as retinoblastoma. Additionally, molecular analysis demonstrated mutations 
of both RB1 alleles, but a different pattern of post-RB1 mutational events from the tumors in 
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the eye in this patient. This difference suggests that the ovarian tumor was of a separate 
clonal origin from the original eye tumor. While the reasons for retinoblastoma arising 
ectopically in ovarian tissue are unclear, primitive neuroectodermal tumors (trilateral 
retinoblastoma) have been documented as second malignancies in survivors of 
retinoblastoma. 
5. Risk factors for the development of second malignancies 
5.1 Rb1 mutation 
Studies have indicated that all retinoblastoma survivors who develop second malignancies 
carry the germinal RB1 mutation, which inactivates the tumor suppressor gene that is 
expressed in all adult tissues. The protein encoded by RB1 functions in multiple cellular 
processes including proliferation, DNA replication, DNA repair, and cell-cycle checkpoint 
control. The timing of initiation of the expression of pRB varies in each cell type, rendering 
patients who carry the RB1 mutation at risk of developing malignancies in nonocular 
tissues. 
Patients who carry the germ-line RB1 mutation (approximately 40% of total retinoblastoma 
patients) have bilateral disease in up to 85% of cases. The remaining 15%, with unilateral 
disease, are also at increased risk for developing second cancers (Abramson et al., 2001). 
Patients with unilateral disease who are at high risk for carrying the germinal mutation, and 
therefore at increased risk for developing a second malignancy, have been identified by 
clinical observation. They consist of patients with a family history of retinoblastoma, 
patients diagnosed within the first 6 months of life, and patients with multifocal disease. 
Advances in mutation analysis have shown that mosaic RB1 mutations are more common 
than previously thought, accounting for at least 5.5 and 3.8% of bilateral and unilateral 
cases, respectively (Rushlow et al., 2009). This has implications for genetic counseling 
conversations, as many patients likely fall on a spectrum of risk for the development of 
second cancers. 
Long-term studies of retinoblastoma survivors in the Netherlands demonstrated a 20.4-fold 
increase in second malignancy compared with the general population (Marees et al. 2008). 
There was not a significant difference in risk of second malignancies between nonhereditary 
survivors and the general population. 
5.2 Retinoma 
Retinoma or retinocytoma is a rare intraocular malignancy that appears to be a benign 
variant of retinoblastoma. These lesions display inactivations of both RB1 allelles and 
represent a step towards retinoblastoma development (Dimaras et al., 2008; Sampieri et al., 
2008). At least 6 cases of patients with a retinoma and a second primary tumor have been 
published in the literature, indicating there is likely an increased risk of second malignancies 
in this population (Korswagen et al., 2004).  
5.3 External beam radiation therapy 
As the primary treatment method for retinoblastoma through much of the latter half of the 
20th century, external beam radiation and its effects on second primary malignancies have 
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been extensively studied. Numerous studies of varying designs have reported a clear 
increase in second nonocular malignancies in patients who have undergone external beam 
radiation (Aerts et al., 2004; Marees et al., 2008; Moll et al., 2001, Wong et al., 1997). 
Kleinerman et al. (Kleinerman et al., 2005) reported that the cumulative risk of a second 
cancer among irradiated hereditary patients was 38% at 50 years compared to 21% among 
non-irradiated hereditary patients. Due to the proximity to the radiation field and 
consequent radiation exposure, there is an increase in head and neck tumors and brain 
tumors in retinoblastoma patients who have been previously irradiated (Abramson, 2005; 
Aerts et al., 2004; Kleinerman et al., 2005; Marees et al., 2009). More recent studies with 
longer follow-up have also demonstrated an increased risk of epithelial neoplasms in this 
population, but these may not be attributed to the effects of radiation (Marees et al., 2008). In 
addition to affecting the location of subsequent tumor development, radiation exposure 
appears to cause an earlier onset of second malignancies (Abramson, 2005; Chauveinc et al., 
2001). Mortality has also been reported to occur earlier as irradiated hereditary 
retinoblastoma patients died sooner than their non-irradiated counterparts with a median 
age of death of 20.5 years and 40 years, respectively (Yu et al., 2009). The dose-dependent 
relationship of radiation administration and the development of second malignancies was 
established over 40 years ago, (Sagerman et al., 1969) and more recent studies have 
confirmed this analysis (Kleinerman et al., 2005; Wong et al., 1997). The age at which 
radiation therapy is administered seems to influence the incidence of second tumor 
development, as patients treated under the age of 1 year were twice as likely to develop a 
second malignancy than those radiated after the age of 1 year (Abramson & Frank, 1998). In 
fact, patients treated with radiation therapy after the first year of life do not seem to have an 
increased risk of second tumor development when compared to those who were never 
irradiated. Because of these effects and advancements in the use of chemotherapy, use of 
external beam radiation therapy has decreased significantly over the last decade. Moreover, 
when it is used, there is a focus on minimizing the radiation dose and limiting the field of 
radiation as much as possible (Chan et al., 2009; Munier et al., 2008). 
5.4 Preventable risk factors 
5.4.1 Sun exposure 
The degree of sunlight exposure has not been directly correlated to the development of 
cutaneous melanoma specifically in survivors of retinoblastoma. However, the known 
association between ultraviolet radiation and cutaneous melanoma in the general 
population combined with the increased incidence of cutaneous melanomas in 
retinoblastoma survivors is sufficient evidence to recommend avoidance of sunlight 
(Trappey et al., 2010). 
5.4.2 Smoking 
Retinoblastoma survivors should be aggressively counseled to refrain from smoking as 
multiple studies have indicated an excess incidence of lung cancer and risk of death from 
lung cancer in relatives of retinoblastoma patients who are carriers of the RB1 gene mutation 
(Sanders et al., 1989; Strong et al., 1984). The elevated risk of lung cancer and the greater risk 
of death from lung cancer were also demonstrated in survivors of hereditary retinoblastoma 
(Fletcher et al., 2004; Kleinerman et al., 2000; Marees et al., 2008; Yu et al., 2009). Moreover, 
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the risk of death in the hereditary survivor population was sevenfold greater than in the 
general population (Fletcher et al., 2004). In 2000, Kleinerman et al. (Kleinerman et al., 2000) 
demonstrated similar smoking rates between the general population and survivors of both 
hereditary and nonhereditary retinoblastoma. However more recently, Foster et al. (Foster et 
al., 2006) reported that hereditary survivors actually smoked significantly less than 
nonhereditary survivors and less than the general United States population. While smoking 
rates in retinoblastoma survivors appear to be improving, it is imperative that physicians 
encourage survivors to quit or abstain from smoking. Counseling on abstinence for smoking 
may also have an effect on the development of bladder cancer in this population, as an 
increased risk for bladder cancer in retinoblastoma survivors has been demonstrated when 
compared with the general population (Frobisher et al., 2010; Kleinerman et al., 2005; 
Marees et al., 2008). While smoking was not specifically associated with bladder cancers in 
this cohort, it has been shown to be the most important environmental risk factor in the 
general population (Hirao et al., 2009). 
5.4.3 CT scans 
The risk of carcinogenesis secondary to radiation exposure from computed tomography 
(CT) has become the focus of increased investigation over the last few decades. 
Epidemiological data suggests that there is a larger attributable lifetime cancer mortality risk 
for children undergoing radiation when compared to adults (Brenner et al., 2001; Mills et al., 
2006). In fact, radiation doses above 50 millisieverts (mSv) in children and 100 mSv in adults, 
which can be attained with repeated imaging, increases the risk for cancer (Pauwels & 
Bourguignon, 2011). The effective dose of CT scans vary from approximately 2 mSv for a 
head CT scan to approximately 20mSv for a CT-based coronary angiography study 
(Pauwels & Bourguignon, 2011). With the amount of scans required for appropriate cancer 
surveillance, retinoblastoma survivors will likely reach doses that increase the risk of cancer. 
Considering the increased risk of developing radiation-induced cancers in patients with a 
germinal RB1 mutation and the increased sensitivity to the carcinogenic effects of radiation 
in children, this cohort should avoid all forms of unnecessary radiation. For these reasons, 
some radiologists are recommending the avoidance of ionizing radiation altogether in 
retinoblastoma survivors and other populations at risk for secondary cancers (Vazquez et 
al., 2003).  
5.5 Controversial risk factors 
5.5.1 Chemotherapy 
Chemotherapy has been part of the treatment regimen for retinoblastoma since the 1950s 
(Reese et al., 1954). Triethylene melamine was the chemotherapeutic agent of choice, often in 
conjunction with radiotherapy, throughout the 1950s and 1960s and was shown to increase 
the development of second tumors outside the field of radiation (Schlienger et al., 2004). In 
the 1990s, many centers began to shift from radiation towards systemic chemotherapy with 
an increasing focus on intra-arterial chemotherapy over the last 5 years. Because of the 
recent shift in management, there are not many long-term studies examining the effects on 
second primary neoplasms. As a result, the role of chemotherapy in the development of 
second cancers remains controversial. Most often current chemotherapy regimens consist of 
vincristine, carboplatin, and an epipodophyllotoxin, either etoposide or tenoposide. 
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Cyclosporine has been used in addition to this combination to decrease the development of 
multidrug resistance. Both platinum-based drugs and topoisomerase inhibitors have been 
reported to increase the risk of second tumors in other primary malignancies ( Hijiya et al., 
2009; Klein et al., 2003; Travis et al., 1999). Some studies have reported the development of 
acute myelogenous leukemia and secondary leukemia in retinoblastoma survivors treated 
with epipodophyllotoxins and alkylating agents, respectively (Gallegos-Castorena et al., 
2002; Gombos et al., 2007; Nishimura et al., 2001; Weintraub et al., 2007). In a study of 187 
patients with hereditary retinoblastoma treated with carboplatin, vincristine +/- etoposide, 
6 patients developed second malignancies (Turaka et al., 2011). Only 1 of these 6 developed 
acute myelogenous leukemia, and that patient was also treated with external beam 
radiation. While this study had a relatively short follow-up, the patients were followed for 
longer than the average latency for development of chemotherapy-related acute 
myelogenous leukemia. Considering this, the authors suggest that the low incidence of 
therapy-based leukemia in this study is reassuring. With the increased use of intra-arterial 
chemotherapy, direct administration via the ophthalmic artery, over the last 5 to 6 years, the 
systemic exposure to chemotherapy is significantly reduced. This may reduce the 
carcinogenic risk of chemotherapy in this population. Further studies are needed to 
elucidate the relationship between both intra-arterial and systemic chemotherapy and 
second malignant neoplasms.  
5.5.2 Growth hormone 
Growth hormone (GH), a treatment often administered to pediatric oncology survivors, has 
mitogenic and proliferogenic properties that may theoretically lead to disease recurrence or 
increased development of secondary neoplasms. Sklar et al. (Sklar et al., 2002) reported that 
treatment with GH for pediatric cancer patients may increase the risk of a secondary solid 
tumor, although the overall increased risk was driven largely by a small subgroup of acute 
leukemia survivors. A follow-up study by Ergun-Longmire et al. (Ergun-Longmire et al., 
2006) concurred with the increased risk of secondary neoplasms but suggested that the risk 
appears to diminish with increasing length of follow-up. In 2002, Abramson et al. 
(Abramson et al., 2002b) reported a case of a metastatic germinal retinoblastoma survivor 
treated with GH who subsequently developed an osteogenic sarcoma. A more recent study 
by Bell et al. (Bell et al., 2009) reported 4.6 second tumor cases per 1000 patient-years of GH 
exposure. Leukemia was the most common primary malignancy associated with secondary 
tumors after growth hormone, but proportionately, retinoblastoma had a higher frequency 
of neoplasms. Five of the sixteen patients with retinoblastoma as the primary neoplasm 
developed secondary cancers. Of these, 4 were previously treated with radiation therapy, 
and only 3 occurred in patients with bilateral retinoblastoma. While these findings are of 
some concern, larger studies examining the risk of secondary cancers in retinoblastoma 
survivors need to be performed to derive conclusive results. 
6. Survival 
Although the survival rates of primary retinoblastoma are continually improving, the 
outcome of second malignancies does not appear to be improving with time. Reulen et al. 
(Reulen et al., 2010) examined the long-term cause-specific mortality among 18,000 
survivors of childhood cancer in Britain, and reported a standardized mortality ratio of 24.7  
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Abbreviation: Rb, retinoblastoma; SMN, secondary malignant neoplasm. §Included hereditary patients 
only. ° Included pineoblastoma as a secondary malignancy. *Adjusted for competing risk of death. 
Table 1. Reported Risk of Second Nonocular Cancers in Retinoblastoma Survivors 
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*Radiation included external beam radiation and brachytherapy in all studies except Marees et al., 2008, 
which did not include brachytherapy as radiation. 
Fig. 1. Pie chart demonstrating the histologic type of reported second malignant neoplasms 
in patients treated with radiation (Acquaviva et al., 2006; Aerts et al., 2004; Kleinerman et al., 
2005; Marees et al., 2008; & Turaka et al., 2011).  Some of these patients may have been 
treated with chemotherapy, but this information was not identified in all of the studies. 
due to second cancer deaths for hereditary retinoblastoma. In the Netherlands, Marees et al. 
(Marees et al., 2009) reported an almost 13-fold increase of second malignancy death 
comparing hereditary retinoblastoma survivors to the general population. As previously 
stated, outcome is particularly grim in patients with trilateral retinoblastoma who have a 
median survival of less than 12 months. A recent long-term study of 1854 retinoblastoma 
survivors from the United States reported a cause-specific cumulative mortality from 
subsequent malignant neoplasms of 26% in hereditary survivors and 1% for nonhereditary 
survivors 50 years after retinoblastoma diagnosis (Yu et al., 2009). An excess in overall 
cancer mortality has also been reported in unilateral sporadic retinoblastoma survivors, 
likely because some of these patients are unilaterally affected RB1 mutation carriers 
(Acquaviva et al., 2006; Yu et al., 2009). While earlier studies reported a higher mortality 
from second tumors in females, more recent studies have indicated an equivalent mortality 
in males and females. 
7. Screening 
Screening practices for secondary tumors in retinoblastoma survivors have not been 
extensively studied and no universal protocol has been determined to date. Sheen et al. 
(Sheen et al., 2008) examined the cancer screening behavior in 875 retinoblastoma survivors. 
The rates of patients ≥40 years who underwent a mammogram within the past 2 years and 
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≥18 years who underwent a Papanicolau smear within the past 3 years were comparable 
between retinoblastoma survivors, other childhood cancer survivors who had received chest 
or mantle irradiation, and the general US population. Hereditary survivors were 3 times 
more likely to undergo an MRI or CT scan as a screening tool for second cancers. 
Neuroimaging with MRI has been recommended as the primary imaging modality, 
particularly in young retinoblastoma survivors, because of the increased risk for second 
malignancies with repeated exposure to ionizing radiation (ie. CT scans). However, a 
prospective study of routine screening with MRI performed in 226 retinoblastoma patients 
did not yield improved outcomes in patients who developed trilateral retinoblastoma 
(Duncan et al., 2001). 
8. Conclusion 
As treatment methods for retinoblastoma continue to evolve, the type and distribution of 
second non-ocular malignancies will continue to change. External beam radiation, once the 
mainstay of primary retinoblastoma management, increases the incidence of and mortality 
from second neoplasms, especially in the head and neck area. With an increased use of 
chemotherapy and longer duration of follow-up, malignancies of epithelial origin may 
become more common in this cohort. The potential for an increase in therapy-related 
leukemia is present with the use of chemotherapy, but additional long-term studies are 
required to assess the validity of this relationship. Survivors of retinoblastoma, particularly 
patients carrying a germinal RB1 mutation or who have a retinoma, should undergo lifelong 
surveillance for second primary tumors. They should also avoid smoking, damaging 
exposure to sunlight, and ionizing radiation when possible. 
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